Skip to main content

Table 1 Baseline characteristics

From: Use of leflunomide in patients with chronic hypersensitivity pneumonitis

Characteristic Total N = 40
Age (years) at initiation of leflunomide 61.5 ± 13.2
Race/Ethnicity
 •African American 2(5.0)
 •Caucasian 37(92.5)
 •Hispanic 1(2.5)
Gender
 •Female 24(60.0)
 •Male 16(40.0)
Smoking history - Tobacco
 •Current smoker 1(2.5)
 •Former 14(35.0)
 •Never 25(62.5)
Is patient known to have antigen exposure?
 •Mold 5(12.5)
 •Avian 13(32.5)
 •Other 3(7.5)
 •Unknown 19(47.5)
Surgical lung biopsy obtained 16(40.0)
Dose of Prednisone, mg 19.8 ± 10.8
PFTs at leflunomide initiation
 •FVC% 66.3 ± 19.2
 •DLCO% 51.4 ± 19.6
CT or HRCT features (N = 28)a
 •Fibrosis > 20% 14 (50.0)
 •Fibrosis ≤20% 4 (14.3)
 •No fibrosis 10(35.7)
Reason for Leflunomide initiation
 •Adverse effect from prior medications 8(20.0)
 •Poor response to prior medications 13(32.5)
 •Started as 1st immunomodulatory agent 15(37.5)
 •Other 4(10.0)
  1. Statistics presented as Mean ± SD or N (% of total). PFT Pulmonary function test, FVC Forced vital capacity, DLCO Diffusing capacity for carbon monoxide, CT Computed tomography, HRCT High-resolution computed tomography
  2. aImaging studies were reviewed for patients who were included for longitudinal analysis (N = 31). Three patients were excluded for missing data